Contribute Try STAT+ Today

A controversial prescription drug pricing bill championed by House Speaker Nancy Pelosi (D-Calif.) would reduce federal spending on Medicare Part D by $345 billion between 2023 and 2029, mostly thanks to a provision that ties prices to what some other countries pay for medicines, according to an analysis released late last week by the Congressional Budget Office.

At the same time, the legislation would have “broad effects” on the pharmaceutical market by “immediately” lowering current and future revenue for drug makers. The agency estimated that a $500 billion to $1 trillion drop in revenue would, in turn, reduce the number of drugs launched by anywhere from eight to 15 over the next decade, since companies could be expected to cut R&D spending.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Yes a number of new drugs will NOT come to market – 8 to 15. However, there is this “The Food and Drug Administration approves, on average, about 30 new drugs annually, suggesting that about 300 drugs might be approved over the next 10 years.” Therefore 5% fewer than the number currently expected to be approved.

Comments are closed.